시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 혈장 프로테아제 C1 억제제 시장 보고서(2025년)
Plasma Protease C1-Inhibitor Global Market Report 2025
상품코드 : 1769712
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,310,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,121,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,932,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

혈장 프로테아제 C1 억제제 시장 규모는 향후 수 년간 급성장할 것으로 예측됩니다. 주된 촉진 요인으로는 맞춤형 치료 접근법의 중시, 임상 파이프라인에서의 C1 억제제 치료의 개발 진행, 예방적 치료법에의 기호성 향상, C1 억제제의 가정용 점적 솔루션 접근성 확대, 수술 전 및 수술에서 C1 억제제 결핍의 인식 증가 등이 포함됩니다.

희귀질환에 대한 투자 증가는 혈장 프로테아제 C1 억제제 시장의 성장을 가속할 것으로 예측됩니다. 투자 증가는 언메트 메디컬 니즈에 대한 인식 증가와 희귀의약품의 지정, 시장 독점권, 개발 비용의 삭감 등 규제상 인센티브에 의해 큰 이익을 얻을 수 있는 가능성에 기인하고 있습니다. 유전성 혈관성 부종과 심각한 증상을 일으킬 수 있는 C1 억제제 결핍과 관련된 기타 드문 질환의 치료를 목적으로 한 연구 개발에 자금을 제공함으로써 혈장 프로테아제 C1 억제제의 개발을 지원하는 것입니다. 2024년 4월, 희귀질환 치료제를 개발하는 기업이 2024년 1분기에 71억 달러를 조달했다고 보고했습니다. 2023년 같은 시기에 조달한 18억 달러에서 307% 증가한 수치입니다.

혈장 프로테아제 C1 억제제 시장의 주요 기업은 유전성 혈관성 부종을 신속하고 효과적으로 완화하고 치료 효과를 높이기 위해 주사용 처방약 등의 선진 제품의 개발에 주력하고 있습니다. 주사 가능한 처방약은 염증을 조절하고 부기를 예방하기 위해 혈장 프로테아제 C1 억제제 수준을 회복하거나 대체하여 주사와 작업을 통해 투여됩니다. 회사인 다케다 약품공업이 인도에서 CINRYZE를 발매했습니다. C1-INH의 혈장 농도를 증가시킴으로써 유전성 혈관성 부종(HAE) 발작의 빈도, 중증도, 지속 시간을 감소시키고, 브라지키닌의 과잉 생산을 방지하고, 그것에 수반되는 부종을 억제합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Plasma protease C1-inhibitors are medications that suppress the activity of plasma protease C1 within the complement system. Their main function is to regulate immune system activity by preventing overactivation of the complement cascade and managing inflammation. These inhibitors help sustain equilibrium within immune and coagulation pathways, thereby protecting tissues from inflammatory damage.

The primary categories of medications that act on plasma protease C1-inhibitor include C1-inhibitors, C1-esterase inhibitors, recombinant inhibitors, kallikrein inhibitors, and selective bradykinin B2 receptor antagonists. C1-inhibitors are naturally occurring blood proteins that modulate the complement system, an essential part of the immune defense against infection and inflammation. These treatments are commonly available in injectable and lyophilized formulations and are distributed through hospital pharmacies, retail drugstores, and online pharmacy platforms.

The plasma protease C1-inhibitor market research report is one of a series of new publications from The Business Research Company that offers insights into plasma protease C1-inhibitor market statistics, including the global market size, regional distribution, leading competitors by market share, detailed market segmentation, industry trends, and emerging opportunities. This comprehensive research report provides an all-encompassing view of the industry, with detailed analysis of both the current landscape and future projections.

The plasma protease C1-inhibitor market size has grown rapidly in recent years. It will grow from $3.37 billion in 2024 to $3.85 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. Factors contributing to this historical growth include the rising prevalence of hereditary angioedema, increased awareness of rare genetic diseases, higher demand for biologics derived from plasma, improved diagnostics for C1-inhibitor deficiency, and expanded use of replacement therapy during emergency interventions.

The plasma protease C1-inhibitor market size is expected to see rapid growth in the next few years. It will grow to $6.53 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. Key drivers in the forecast period include a heightened emphasis on personalized treatment approaches, ongoing development of C1-inhibitor therapies in clinical pipelines, increasing preference for preventative treatment methods, broader access to at-home infusion solutions for C1-inhibitors, and greater recognition of C1-inhibitor deficiencies in preoperative and surgical contexts. Notable trends anticipated include a rise in orphan drug designations, advancements in low-immunogenicity drug formulations, incorporation of genomic technologies, expansion into telehealth platforms, and innovation in long-duration C1-inhibitor therapies.

The increasing investment in rare diseases is expected to drive the growth of the plasma protease C1-inhibitor market. Rare diseases are health conditions that impact a small percentage of the population, typically fewer than 1 in 2,000 individuals. These conditions are often chronic, progressive, and can be life-threatening or disabling. The rise in investment stems from the growing awareness of unmet medical needs and the potential for substantial returns through regulatory incentives such as orphan drug designation, market exclusivity, and lower development costs. This investment supports the development of plasma protease C1-inhibitors by funding research and innovation aimed at treating hereditary angioedema and other rare conditions linked to C1-inhibitor deficiencies, which can cause severe symptoms. For example, in April 2024, Global Genes, a US-based nonprofit organization, reported that companies developing drugs for rare diseases raised $7.1 billion in the first quarter of 2024, a 307% increase from the $1.8 billion raised in the same period in 2023. As a result, the increasing investment in rare diseases is propelling the plasma protease C1-inhibitor market forward.

Leading companies in the plasma protease C1-inhibitor market are concentrating on the development of advanced products, such as injectable prescription medicines, to provide rapid and effective relief for hereditary angioedema and enhance treatment results. Injectable prescription medicines are administered through injection and work by restoring or replacing plasma protease C1-inhibitor levels to control inflammation and prevent swelling episodes. For instance, in December 2022, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical firm, introduced CINRYZE in India. CINRYZE is the first injectable C1 esterase inhibitor approved by the FDA for prophylactic treatment in patients aged six years and older. It helps reduce the frequency, severity, and duration of hereditary angioedema (HAE) attacks by increasing plasma levels of C1-INH, thereby preventing excessive bradykinin production and controlling the associated swelling.

In December 2023, Danaher Corporation, a US-based conglomerate, acquired Abcam plc for $5.7 billion. This acquisition was intended to strengthen Danaher's life sciences portfolio by improving its protein research tools and accelerating progress in disease mapping and drug discovery. Abcam plc is a UK-based biotechnology firm that offers various products related to plasma protease C1-inhibitor.

Major players in the plasma protease c1-inhibitor market are Takeda Pharmaceutical Company Limited, CSL Behring LLC, Sigma-Aldrich Co. LLC, Octapharma AG, Bio-Techne Corp, Ionis Pharmaceuticals Inc., Sanquin, Biotest AG, BioCryst Pharmaceuticals Inc., Pharming Group N.V., Sino Biological Inc, Cayman Chemical, Enzo Life Sciences Inc, KalVista Pharmaceuticals Inc., Santa Cruz Biotechnology Inc, Pharvaris N.V, Attune Pharmaceuticals Inc., Biorbyt Ltd, Adverum Biotechnologies Inc, and Lev Pharmaceuticals.

North America was the largest region in the plasma protease C1-inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in plasma protease C1-inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the plasma protease C1-inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The plasma protease C1-inhibitor market consists of sales of berinert, cinryze, haegarda, firazyr, and lcatibant. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Plasma Protease C1-Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on plasma protease c1-inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for plasma protease c1-inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The plasma protease c1-inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Plasma Protease C1-Inhibitor Market Characteristics

3. Plasma Protease C1-Inhibitor Market Trends And Strategies

4. Plasma Protease C1-Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Plasma Protease C1-Inhibitor Growth Analysis And Strategic Analysis Framework

6. Plasma Protease C1-Inhibitor Market Segmentation

7. Plasma Protease C1-Inhibitor Market Regional And Country Analysis

8. Asia-Pacific Plasma Protease C1-Inhibitor Market

9. China Plasma Protease C1-Inhibitor Market

10. India Plasma Protease C1-Inhibitor Market

11. Japan Plasma Protease C1-Inhibitor Market

12. Australia Plasma Protease C1-Inhibitor Market

13. Indonesia Plasma Protease C1-Inhibitor Market

14. South Korea Plasma Protease C1-Inhibitor Market

15. Western Europe Plasma Protease C1-Inhibitor Market

16. UK Plasma Protease C1-Inhibitor Market

17. Germany Plasma Protease C1-Inhibitor Market

18. France Plasma Protease C1-Inhibitor Market

19. Italy Plasma Protease C1-Inhibitor Market

20. Spain Plasma Protease C1-Inhibitor Market

21. Eastern Europe Plasma Protease C1-Inhibitor Market

22. Russia Plasma Protease C1-Inhibitor Market

23. North America Plasma Protease C1-Inhibitor Market

24. USA Plasma Protease C1-Inhibitor Market

25. Canada Plasma Protease C1-Inhibitor Market

26. South America Plasma Protease C1-Inhibitor Market

27. Brazil Plasma Protease C1-Inhibitor Market

28. Middle East Plasma Protease C1-Inhibitor Market

29. Africa Plasma Protease C1-Inhibitor Market

30. Plasma Protease C1-Inhibitor Market Competitive Landscape And Company Profiles

31. Plasma Protease C1-Inhibitor Market Other Major And Innovative Companies

32. Global Plasma Protease C1-Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Plasma Protease C1-Inhibitor Market

34. Recent Developments In The Plasma Protease C1-Inhibitor Market

35. Plasma Protease C1-Inhibitor Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기